Host Species:	Rabbit
Concentration:	1 mg/ml (OD 1.35 / 280 nm)
Antigen:	Human Apolipoprotein CIII
Purification:	Affinity purified
Buffer:	75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity	Specifically binds to human apo CIII. Dilution for immunoblot and ELISA range: 1,000 to 40,000.
Use:	The antibody can be used for detection of apo CIII in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).

It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.

Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .

Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.

Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.

 

Citations

[A12][A13]	2020	Liu, Gang; Zhang, Bo; Hu, Yang; Rood, Jennifer; Liang, Liming; Qi, Lu et al. (2020): Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study. In Environmental Health : a global access science source 19 (1), p. 5. DOI: 10.1186/s12940-020-0561-8.
[A12][A13]	2020	Du, Yu; Li, Xingxing; Su, Chunyan; Xi, Mei; Zhang, Xiumin; Jiang, Zhibo et al. (2020): Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice. British Journal of Pharmacology 177 (8), pp. 1754–1772. DOI: 10.1111/bph.14933.
[A12][A13]	2020	Koch, Manja; DeKosky, Steven T.; Goodman, Matthew; Sun, Jiehuan; Furtado, Jeremy D.; Fitzpatrick, Annette L. et al. (2020): Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia. JAMA Network Open 3 (7), e209250. DOI: 10.1001/jamanetworkopen.2020.9250.
[A12][A13]	2020	Koch, Manja; DeKosky, Steven T.; Goodman, Matthew; Sun, Jiehuan; Furtado, Jeremy D.; Fitzpatrick, Annette L. et al. (2020): High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. J. Lipid Res. 61 (3), pp. 445–454. DOI: 10.1194/jlr.P119000473.
[A12][A13]	2020	Lee, An-Sheng; Wang, Yu-Chen; Chang, Shih-Sheng; Lo, Ping-Hang; Chang, Chia-Ming; Lu, Jonathan et al. (2020): Detection of a High Ratio of Soluble to Membrane-Bound LOX-1 in Aspirated Coronary Thrombi From Patients With ST-Segment-Elevation Myocardial Infarction. Journal of the American Heart Association 9 (2), e014008. DOI: 10.1161/JAHA.119.014008.
[A12][A13]	2019	Kegulian, Natalie C.; Ramms, Bastian; Horton, Steven; Trenchevska, Olgica; Nedelkov, Dobrin; Graham, Mark J. et al. (2019): ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Arterioscler Thromb Vasc Biol. 39 (10), pp. 2145–2156. DOI: 10.1161/ATVBAHA.119.312723.
[A12][A13]	2018	Aroner, Sarah A.; Koch, Manja; Mukamal, Kenneth J.; Furtado, Jeremy D.; Stein, James H.; Tattersall, Matthew C. et al. (2018): High‐Density Lipoprotein Subspecies Defined by Apolipoprotein C‐III and Subclinical Atherosclerosis Measures: MESA (The Multi‐Ethnic Study of Atherosclerosis). In Journal of the American Heart Association 7 (6), p. 40. DOI: 10.1161/JAHA.117.007824.
[A12][A13]	2018	Furtado, Jeremy D.; Yamamoto, Rain; Melchior, John T.; Andraski, Allison B.; Gamez-Guerrero, Maria; Mulcahy, Patrick et al. (2018): Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies. In Arterioscler Thromb Vasc Biol. 38 (12), pp. 2827–2842. DOI: 10.1161/ATVBAHA.118.311607.
[A12][A13]	2018	Kim, KyeongJin; Goldberg, Ira J.; Graham, Mark J.; Sundaram, Meenakshi; Bertaggia, Enrico; Lee, Samuel X. et al. (2018): γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. In Cell Metabolism 27 (4), 816-827.e4. DOI: 10.1016/j.cmet.2018.02.010.
[A12][A13]	2018	Koch, Manja; DeKosky, Steven T.; Fitzpatrick, Annette L.; Furtado, Jeremy D.; Lopez, Oscar L.; Kuller, Lewis H. et al. (2018): Apolipoproteins and Alzheimer"s pathophysiology. In Alzheimer"s & Dementia (Amsterdam, Netherlands) 10, pp. 545–553. DOI: 10.1016/j.dadm.2018.07.001.
[A12][A13]	2018	Morton, Allyson M.; Koch, Manja; Mendivil, Carlos O.; Furtado, Jeremy D.; Tjønneland, Anne; Overvad, Kim et al. (2018): Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. In JCI Insight 3 (4). DOI: 10.1172/jci.insight.98045.
[A12][A13]	2017	Koch, Manja; Furtado, Jeremy D.; Falk, Kim; Leypoldt, Frank; Mukamal, Kenneth J.; Jensen, Majken K. (2017): Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. In Alzheimer"s & Dementia (Amsterdam, Netherlands) 6, pp. 182–187. DOI: 10.1016/j.dadm.2017.01.007.
[A12][A13]	2017	Lee, Chan Joo; Choi, Seungbum; Cheon, Dong Huey; Kim, Kyeong Yeon; Cheon, Eun Jeong; Ann, Soo-jin et al. (2017): Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. In Lipids Health Dis 16 (1), p. 49. DOI: 10.1186/s12944-017-0433-6.
[A12][A13]	2017	Sundaram, Meenakshi; Curtis, Kaitlin R.; Amir Alipour, Mohsen; LeBlond, Nicholas D.; Margison, Kaitlyn D.; Yaworski, Rebecca A. et al. (2017): The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. In Journal of Lipid Research 58 (11), pp. 2188–2196. DOI: 10.1194/jlr.M077313.
[A12][A13]	2017	Wassef, Hanny; Bissonnette, Simon; Dufour, Robert; Davignon, Jean; Faraj, May (2017): Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. In J. Nutr. 147 (5), pp. 754–762. DOI: 10.3945/jn.116.242750.
[A12][A13]	2016	Koska, Juraj; Yassine, Hussein; Trenchevska, Olgica; Sinari, Shripad; Schwenke, Dawn C.; Yen, Frances T. et al. (2016): Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. In Journal of Lipid Research 57 (5), pp. 894–905. DOI: 10.1194/jlr.P064816.
[A12][A13]	2015	Trenchevska, Olgica; Schaab, Matthew R.; Nelson, Randall W.; Nedelkov, Dobrin (2015): Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. In Methods (San Diego, Calif.) 81, pp. 86–92. DOI: 10.1016/j.ymeth.2015.02.020.
[A12][A13]	2015	Yassine, Hussein N.; Trenchevska, Olgica; Ramrakhiani, Ambika; Parekh, Aarushi; Koska, Juraj; Walker, Ryan W. et al. (2015): The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. In PLoS ONE 10 (12), e0144138. DOI: 10.1371/journal.pone.0144138.
[A12][A13]	2014	Lee, An-Sheng; Chen, Wei-Yu; Chan, Hua-Chen; Hsu, Jing-Fang; Shen, Ming-Yi; Chang, Chia-Ming et al. (2014): Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL. In Cardiovascular Diabetology 13, p. 64. DOI: 10.1186/1475-2840-13-64.
[A12][A13]	2014	Talayero, Beatriz; Wang, Liyun; Furtado, Jeremy; Carey, Vincent J.; Bray, George A.; Sacks, Frank M. (2014): Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. In J. Lipid Res. 55 (10), pp. 2167–2177. DOI: 10.1194/jlr.M042333.
[A12][A13]	2014	Wang, Liyun; Sacks, Frank M.; Furtado, Jeremy D.; Ricks, Madia; Courville, Amber B.; Sumner, Anne E. (2014): Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins. In Nutrition & Metabolism 11 (1), p. 56. DOI: 10.1186/1743-7075-11-56.
[A12][A13]	2013	Sumner, Anne E.; Furtado, Jeremy D.; Courville, Amber B.; Ricks, Madia; Younger-Coleman, Novie; Tulloch-Reid, Marshall K.; Sacks, Frank M. (2013): ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women. In Nutrition & Metabolism 10 (1), p. 73. DOI: 10.1186/1743-7075-10-73.
[A12][A13]	2013	Zheng, Chunyu; Azcutia, Veronica; Aikawa, Elena; Figueiredo, Jose-Luiz; Croce, Kevin; Sonoki, Hiroyuki et al. (2013): Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. In European Heart Journal 34 (8), pp. 615–624. DOI: 10.1093/eurheartj/ehs271.
[A12][A13]	2012	Jensen, Majken K.; Rimm, Eric B.; Furtado, Jeremy D.; Sacks, Frank M. (2012): Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. In Journal of the American Heart Association 1 (2). DOI: 10.1161/JAHA.111.000232.
[A12][A13]	2012	Krauss, Ronald M.; Wojnooski, Kathleen; Orr, Joseph; Geaney, J. Casey; Pinto, Cathy Anne; Liu, Yang et al. (2012): Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. In J. Lipid Res. 53 (3), pp. 540–547. DOI: 10.1194/jlr.M018010.
[A12][A13]	2012	Wada, Yoshinao; Kadoya, Machiko; Okamoto, Nobuhiko (2012): Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. In Glycobiology 22 (8), pp. 1140–1144. DOI: 10.1093/glycob/cws086.
[A12][A13]	2011	Holmberg, R.; Refai, E.; Hoog, A.; Crooke, R. M.; Graham, M.; Olivecrona, G. et al. (2011): Lowering apolipoprotein CIII delays onset of type 1 diabetes. In J. Biol. Chem. 108 (26), pp. 10685–10689. DOI: 10.1073/pnas.1019553108.
[A12][A13]	2011	Mendivil, Carlos O.; Rimm, Eric B.; Furtado, Jeremy; Chiuve, Stephanie E.; Sacks, Frank M. (2011): Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. In Circulation 124 (19), pp. 2065–2072. DOI: 10.1161/CIRCULATIONAHA.111.056986.
[A12][A13]	2011	Qin, Wen; Sundaram, Meenakshi; Wang, Yuwei; Zhou, Hu; Zhong, Shumei; Chang, Chia-Ching et al. (2011): Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. In J. Biol. Chem. 286 (31), pp. 27769–27780. DOI: 10.1074/jbc.M110.203679.
[A12][A13]	2010	Furtado, Jeremy D.; Campos, Hannia; Sumner, Anne E.; Appel, Lawrence J.; Carey, Vincent J.; Sacks, Frank M. (2010): Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. In The American Journal of Clinical Nutrition 92 (4), pp. 714–722. DOI: 10.3945/ajcn.2009.28532.
[A12][A13]	2010	Jayanthi, S.; Buie, S.; Moore, S.; Herning, R. I.; Better, W.; Wilson, N. M. et al. (2010): Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses. In Molecular Psychiatry 15 (1), pp. 101–112. DOI: 10.1038/mp.2008.50;
[A12][A13]	2010	Sundaram, Meenakshi; Zhong, Shumei; Bou Khalil, Maroun; Zhou, Hu; Jiang, Zhenghui G.; Zhao, Yang et al. (2010): Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. In J. Lipid Res. 51 (6), pp. 1524–1534. DOI: 10.1194/jlr.M005108.
[A12][A13]	2010	Sundaram, Meenakshi; Zhong, Shumei; Khalil, Maroun Bou; Links, Philip H.; Zhao, Yang; Iqbal, Jahangir et al. (2010): Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. In J. Lipid Res. 51 (1), pp. 150–161. DOI: 10.1194/jlr.M900346-JLR200.
[A12][A13]	2008	Deng, Ting; Ji, Wei; Lian, Ji-Hong; Guo, Lei; Hu, Wei-Rong; Qian, Ming; Gong, Bang-qiang (2008): Identifying Natural Derived Upregulators of Human ApoA-I Expression via a Cell-Based Drug Screening System. In Pharmaceutical Biology 46 (9), pp. 610–615. DOI: 10.1080/13880200802179584.
[A12][A13]	2008	Furtado, Jeremy D.; Campos, Hannia; Appel, Lawrence J.; Miller, Edgar R.; Laranjo, Nancy; Carey, Vincent J.; Sacks, Frank M. (2008): Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial. In The American Journal of Clinical Nutrition 87 (6), pp. 1623–1630. DOI: 10.1093/ajcn/87.6.1623.
[A12][A13]	2008	Ruiz-Narváez, Edward A.; Sacks, Frank M.; Campos, Hannia (2008): Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. In The American Journal of Clinical Nutrition 87 (6), pp. 1932–1938. DOI: 10.1093/ajcn/87.6.1932.
[A12][A13]	2007	Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[A12][A13]	2007	Gaubatz, John W.; Gillard, Baiba K.; Massey, John B.; Hoogeveen, Ron C.; Huang, Max; Lloyd, Eric E. et al. (2007): Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). In J. Lipid Res. 48 (2), pp. 348–357. DOI: 10.1194/jlr.M600249-JLR200.
[A12][A13]	2006	Guo, Lei; Hu, Wei-Rong; Lian, Ji-Hong; Ji, Wei; Deng, Ting; Qian, Ming; Gong, Bang-qiang (2006): Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. In European Journal of Pharmacology 551 (1-3), pp. 80–86. DOI: 10.1016/j.ejphar.2006.08.048.
[A12][A13]	2006	Kawakami, Akio; Aikawa, Masanori; Alcaide, Pilar; Luscinskas, Francis W.; Libby, Peter; Sacks, Frank M. (2006): Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. In Circulation 114 (7), pp. 681–687. DOI: 10.1161/CIRCULATIONAHA.106.622514.
[A12][A13]	2006	Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.
[A12][A13]	2006	Schaap, Frank G.; Nierman, Melchior C.; Berbée, Jimmy F. P.; Hattori, Hiroaki; Talmud, Philippa J.; Vaessen, Stefan F. C. et al. (2006): Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. In J. Lipid Res. 47 (10), pp. 2333–2339. DOI: 10.1194/jlr.M500533-JLR200.
[A12][A13]	2005	Nedelkov, Dobrin; Kiernan, Urban A.; Niederkofler, Eric E.; Tubbs, Kemmons A.; Nelson, Randall W. (2005): Investigating diversity in human plasma proteins. In Proc Natl Acad Sci USA 102 (31), pp. 10852–10857. DOI: 10.1073/pnas.0500426102.
[A12][A13]	2004	Juntti-Berggren, Lisa; Refai, Essam; Appelskog, Ioulia; Andersson, Mats; Imreh, Gabriela; Dekki, Nancy et al. (2004): Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. In Proc Natl Acad Sci USA 101 (27), pp. 10090–10094. DOI: 10.1073/pnas.0403551101.
[A12][A13]	2003	Malek, Goldis; Li, Chuan-Ming; Guidry, Clyde; Medeiros, Nancy E.; Curcio, Christine A. (2003): Apolipoprotein B in Cholesterol-Containing Drusen and Basal Deposits of Human Eyes with Age-Related Maculopathy. In The American Journal of Pathology 162 (2), pp. 413–425. DOI: 10.1016/S0002-9440(10)63836-9.
[A12][A13]	2003	Yang, Chao-Yuh; Raya, Joe L.; Chen, Hsin-Hung; Chen, Chu-Huang; Abe, Yasunori; Pownall, Henry J. et al. (2003): Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. In Arterioscler Thromb Vasc Biol. 23 (6), pp. 1083–1090. DOI: 10.1161/01.ATV.0000071350.78872.C4.
[A12][A13]	2001	Deeg, M. A.; Bierman, E. L.; Cheung, M. C. (2001): GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. In J. Lipid Res. 42 (3), pp. 442–451.

academy biomed产品信息-载脂蛋白脂蛋白和载脂蛋白的一般信息血浆脂蛋白类别可以根据其分离的密度来定义，包括高（HDL），低（LDL），中间（IDL），极低密度脂蛋白（VLDL）和乳糜微粒。通常，脂蛋白颗粒的大小范围为10至1000 nm。它们由含有胆固醇酯，甘油三酸酯，脂肪酸和脂溶性维生素的疏水核组成。周围的亲水层由各种载脂蛋白，磷脂和胆固醇组成。载脂蛋白可以通过从脂蛋白脱脂而分离，并且已经建立了许多制备方法，例如凝胶过滤或DEAE色谱法。 脂蛋白 载脂蛋白高密度脂蛋白apoAI，AII，AIV，apoCI，CII，CIII，apoD和apoE低密度脂蛋白载脂蛋白B-100极低密度脂蛋白apoB-100，apoCI，CII，CIII和apoE乳糜微粒apoAI，AII，AIV，apoB-48，apoCI，CII，CIII，apoE和apoH 1.载脂蛋白AI（ApoAI）ApoAI约占HDL中蛋白质部分的70％。它是一条单链多肽，由243个氨基酸组成，没有二硫键结合，谷氨酸为C末端残基，天冬氨酸为N末端残基。据报道分子量为28kDa（Brewer等，1978）。ApoAI激活卵磷脂-胆固醇（LCAT）酰基转移酶，该酶负责血浆中的胆固醇酯化。ApoAI水平可能与冠状动脉疾病的风险成反比。 2.载脂蛋白AII（ApoAII）ApoAII在HDL中占ApoAI的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，大型欧洲前瞻性研究中的病例对照研究表明，血浆apoAII浓度与冠心病事件密切相关（Birjmohun等，2007）。 3.载脂蛋白B（ApoB）ApoB在人血浆中以两种亚型存在，即ApoB-48（Chen等，1987）和ApoB-100（Wei等，1985，Yang等，1986a; 1989a，b; 1990; Chen等，1990）。 1986； Yang等，1990； Yang和Pownall，1992）。ApoB-100是LDL受体的主要生理配体。ApoB100是一种大型单体蛋白，包含4536个氨基酸（分子量515 kDa，Yang等，1986b）。ApoB-100在肝脏中合成，是VLDL组装所必需的。在去除apoA，E和C后，在LDL和VLDL中发现了它。乳糜微粒及其残留物中存在ApoB-48。它对于膳食脂质的肠道吸收至关重要。ApoB水平与冠心病的风险相关。ApoB-48在小肠中合成。 4.载脂蛋白CI（ApoCI）ApoCI包含57个氨基酸残基，mw为6.6 kDa（Jackson等，1974）。已经发现ApoCI可以激活LCAT（Liu和Subbaiah 1993）并抑制胆固醇酯转移酶，该酶可能调节几种脂肪酶（Poensgen，1990; Conde-Knape等，2002; Berbee等，2005）。 5.载脂蛋白CII（ApoCII）ApoCII包含78个氨基酸残基。mw为8.5 kDa（Jackson等，1977）。ApoCII激活脂蛋白脂肪酶，该酶水解乳糜微粒中三酰基甘油中的脂肪酸。 6.载脂蛋白CIII（ApoCIII）ApoCIII包含79个氨基酸残基。mw为8.7 kDa（Brewer等，1974）。它可能会抑制apoCIII激活脂蛋白脂肪酶。ApoCIII是循环中含apoB和含apoAI的脂蛋白的组成部分。ApoCIII在调节VLDL，IDL和LDL的血浆代谢中起着关键作用，主要是通过抑制受体介导的肝脏对这些脂蛋白的摄取（Sehayek和Eisenberg 1991，Aalto-Setala等人，1992，Zheng等人。 ，2007） 7.载脂蛋白E（ApoE）ApoE包含299个氨基酸残基。它是一种34-37 kDa的糖基化蛋白（Rall等，1983）。ApoE与甘油三酸酯，磷脂，胆固醇酯和胆固醇在细胞内外的转运有关，并且是LDL受体的配体。ApoE也与免疫和神经变性有关。已经发现抑制淋巴细胞增殖。已发现晚期家族性和偶发性阿尔茨海默病患者的三种常见ApoE亚型之一ApoE4发生率更高。已在阿尔茨海默氏病患者的老年斑和神经原纤维缠结中检测到ApoE4亚型。ApoE4与乳糜微粒残留的快速清除和总胆固醇水平升高有关。 8.载脂蛋白（a）[载脂蛋白（a）]人脂蛋白[a]，Lp [a]的血浆浓度与冠状动脉疾病高度相关。Lp [a]的蛋白质部分apoLp [a]由两个载脂蛋白apo [a]和apoB-100组成，它们通过一个或多个二硫键连接。Apo [a]是Lp [a]特有的蛋白质，以多态性形式存在，其表观分子量从419 kDa到838 kDa不等（Gaubatz等，1983； 1990，1993）。 9.纤溶酶原纤溶酶原包含810个氨基酸残基。它是分子量为90 kDa的单链糖蛋白（Robbins等，1967），可溶于水。由经认证测试显示对HBsAg以及HIV和HCV抗体呈阴性的血浆制备。纤溶酶原是蛋白酶纤溶酶的无活性前体。纤溶酶原通过组织纤溶酶原激活物（tPA）的作用被激活，后者主要激活纤溶酶的纤溶活性（血栓溶解），而尿激酶纤溶酶原激活物（uPA）与细胞外基质重塑和细胞迁移有关。 10. C反应蛋白（CRP）人C反应蛋白（CRP）是预测未来心血管事件（如心脏病和中风）的重要生物标志物（Koenig等，1999； Jenny等，2007； Kabagambe等。2011）。CRP是肝脏产生的急性期蛋白。它是五味素蛋白家族的成员，具有五个相同的非糖基化亚基，每个亚基具有206个氨基酸（mw 23 kDa）（Agrawal等，2009）。在炎症的其他标志物中，CRP与心血管事件之间的关联最强（Marsik等，2008； Kones等，2010）。临床研究表明，不稳定型心绞痛和CRP升高的患者的冠心病死亡率明显高于CRP升高的患者。它是检测处于斑块性高风险的个体的重要生物标志物。 11.伊里辛运动诱导型肌动蛋白鸢尾素（Boström等人，2012）是通过从跨膜前体FNDC5裂解而分泌的。循环鸢尾素控制着与褐变，血管生成，伤口愈合，骨量和新陈代谢有关的多种细胞过程。